The anti‐GRP78 monoclonal immunoglobulin M antibody PAT‐SM6 has completed Phase I trials for multiple myeloma (NCT01727778) and melanoma (ACTRN12610000733077) and showed good safety and tolerability [217]. This evidence concerns the gene HSPA5 and plasma cell myeloma.